Abbvie Inc.

Edit Tarcsa

Chung-Ming Hsieh

Jennifer Maria Perez

Yuliya Kutskova

John Memmott

Anwar Murtaza

Anca Clabbers

Suju Zhong

Margaret Hugunin

Mary Leddy

Bradford L McRae

Craig Wallace

Shaughn H Bryant

Charles W Hutchins

Maria Harris

Jianwei Shen

Eileen Belanger

William B Stine

Jjijie Gu

Rong-rong Zhu

Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

IL-17 binding proteins

Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

The present invention encompasses prostaglandin E(PGE) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin Eand neutralize prostaglandin Eactivity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin Eand for inhibiting prostaglandin Eactivity, e.g., in a human subject suffering from a disorder in which prostaglandin Eactivity is detrimental.

Prostaglandin E2 binding proteins and uses thereof

Growing community of inventors

Westborough, MA, United States of America

Edit Tarcsa